STAMFORD, Conn., June 11 /PRNewswire-FirstCall/ — Zargis
Medical Corp., a majority-owned subsidiary of Speedus Corp.
(Nasdaq: SPDE), today announced that it has entered into
an agreement with Boston-based
Stethographics, Inc. providing an exclusive license to patented,
FDA-cleared Stethographics lung sounds analysis technology that
automatically identifies clinically significant respiratory sounds.
Zargis plans to incorporate the technology into its existing
telemedicine and computer-aided auscultation platform in order to
deliver these new diagnostic support tools to medical
professionals.
Stethographics is a leading developer of automated, noninvasive
sound analysis products designed to help medical professionals
identify and interpret clinically significant lung sounds. The
company was founded in 1998 by Dr. Raymond
Murphy, a Professor of Medicine at Tufts University School of Medicine who also
spent 25 years as an assistant professor at the Harvard School of Public Health.
The licensed technology allows lung sounds to be visually
displayed in the form of traces, similar to the manner in which the
Zargis Cardioscan heart murmur detection software displays
stethoscope-captured heart sounds. The system also provides
objective findings regarding clinically significant respiratory
sounds such as wheezes, crackles and rhonchi. “We are excited to
have partnered with Zargis Medical. Their award-winning platform
has set a new standard for computer-aided sound analysis and
tele-auscultation, and the inclusion of our technology in their
systems should greatly aid healthcare profession
‘/>”/>
